Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that adding a topical agent to intense pulsed light therapy significantly improved hair reduction and patient satisfaction in Pakistani women with idiopathic facial hirsutism compared to light therapy alone, without increasing adverse effects.

This article discusses various limitations of direct-to-consumer teledermatology platforms, highlighting concerns regarding ethical issues, financial conflicts of interest, and challenges in providing comprehensive patient care compared to traditional in-person consultations.

Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.

This case report presents the first successful treatment of perifolliculitis capitis abscedens et suffodiens using a regimen of adalimumab and baricitinib, resulting in almost complete healing after nine months.

In this case report, researchers described a two-year-old girl with Vitamin D dependent rickets Type II, noting elevated 1,25-dihydroxyvitamin D3 and alopecia, and observed limited treatment response likely due to poor compliance.

This case report identifies a 23-year-old man with congenital triangular alopecia, a non-scarring alopecia characterized by preserved follicles and vellus hair, for which unnecessary interventions should be avoided.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This article discusses the limitations in the design or mechanism of hair implanter pens and reports no new findings.

Direct-to-consumer teledermatology is not effectively reaching underserved populations due to language, technology, and insurance barriers.

This study found that oral setipiprant was safe but did not improve scalp hair growth compared to placebo in men with androgenetic alopecia.

This review highlights the ongoing need for novel treatments for autosomal recessive congenital ichthyoses, suggesting that drug repositioning, utilizing existing medications or biologics, could provide more affordable and effective options for managing this lifelong skin condition.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

This study found that treatment with cyproterone acetate and estradiol improved emotional well-being and acceptance of being viewed among women with hirsutism, with no significant differences between oral and transdermal estradiol groups.

This study found that individuals with alopecia areata had significantly higher serum levels of retinol-binding protein 4 and increased IgG immunoreactivity against it, suggesting a role in the disease's pathogenesis.

This study observed that baricitinib treatment led to significant improvements in hair regrowth and quality of life scores in adults with severe alopecia areata over 24 weeks, with an acceptable safety profile as most adverse effects were transient.

This article reports a case where the IOP-lowering drug bimatoprost was associated with eyelash hypertrichosis.

This study found that a hair mask made from bitter gourd effectively reduced hair loss and dandruff among participants, though the authors note the need for clinical trials and durability tests for further validation.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

This study found that Arabidopsis thaliana plants developed longer root hairs under low phosphorus conditions, suggesting auxin involvement in this adaptive response.

In this study, a single subcutaneous dose of PTH-CBD showed similar hair regrowth to daily oral ruxolitinib in mice with alopecia, possibly through increased beta-catenin and anagen transition stimulation.

In this study using mouse models, researchers found that stress-related hair loss may occur due to CRH-induced PTEN loss and inhibition of autophagy via the PI3K/AKT/mTOR pathway in dermal papilla cells, suggesting potential treatments through PTEN activation or autophagy enhancement.

In this study, hirsutism negatively affected quality of life in Turkish patients, as measured by the Dermatology Life Quality Index, although no significant relationship was observed between the severity of hirsutism and quality of life scores.

This descriptive longitudinal study conducted in a Kolkata hospital found that intense pulsed light treatment significantly improved hirsutism in patients, as evaluated by trichoscopy and visual analog scores, demonstrating its effectiveness and safety for hair removal, independent of medical treatment.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

This case report describes reversible hair loss in a patient taking aripiprazole, suggesting this side effect may be common among psychotropic medications.

Alopecia areata significantly strains healthcare and finances in the UAE, needing better management.

In this study, the authors discuss that while traditional alopecia areata treatments like corticosteroids offer limited efficacy and pose long-term adverse effects, new treatments using janus kinase inhibitors show potential for changing treatment protocols, pending a better understanding of associated adverse drug events.